Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Alizyme

Status and phase: Completed; Phase 1

Conditions: Obesity

Treatments: Drug: ATL-962

Study type: Interventional

Funder types: Industry

Identifiers

NCT00148382

ATL-962/191/CL

Details and patient eligibility

About

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Full description

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Obese, otherwise-healthy subjects
• Body mass index 30-45kg/m2

Exclusion criteria

• Women who are pregnant or breast feeding
• Any drug treatment within 2 weeks of commencement of dosing in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind